Patent 10258637 was granted and assigned to Boehringer Ingelheim on April, 2019 by the United States Patent and Trademark Office.
The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).